All In Biotech

Drug Trial Radar · NCT03682471

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

Long-term, Follow-up Study of Subjects Who Completed Phase III Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area

Last checked: Nov 19, 2026Latest source record: Sep 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

201

Actual

Start

Feb 14, 2012

Primary completion

Dec 13, 2013

Study completion Dec 13, 2013

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 24, 2018

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this non-treatment, placebo-controlled, observational, 24-month follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study. Participants who previously received deoxycholic acid injections in studies ATX-101-10-16 \[NCT01305577\] or ATX-101-10-17 \[NCT01294644\] were enrolled in this non-treatment observational follow-up study to further evaluate safety and efficacy.

Conditions

  • Subcutaneous Fat

Interventions

  • Deoxycholic acid InjectionDrug

    Solution for subcutaneous injection.

  • PlaceboDrug

    Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Maintaining Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were CR-SMFRS 1-Grade Responders at both LTFU Baseline and at 24-Month VisitTime frame: LTFU Baseline (Month 0) to Month 24
  2. Percentage of Participants with Maintenance of Response as Assessed by the Subject Satisfaction Rating Scale (SSRS) During the 24 Months of Follow up, i.e. % of Participants who were SSRS Responders at both LTFU Baseline and at 24-Month VisitTime frame: LTFU Baseline (Month 0) to Month 24

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Licca Clinical Research Institute

    Augsburg, Germany

  • Campus Charité Mitte, Klinik für Dermatologie, Venerologie und Allergologie

    Berlin, Germany

  • Ruhruniversität Bochum - St. Josef Hospital

    Bochum, Germany

  • Klinikum Darmstadt

    Darmstadt, Germany

  • Krankenhaus Dresden- Friedrichstadt Klinik für Dermatologie und Allergologie

    Dresden, Germany

  • Dr. Beatrice Gerlach

    Dresden, Germany

  • Klinikum der Johann-Wolfgang Goethe-Universität - Klinik für Dermatologie, Venerologie und Allergologie

    Frankfurt, Germany

  • Hautarztpraxis Cutanis

    Freiburg im Breisgau, Germany

  • Universitätsklinik Schleswig Holstein, Campus Luebeck, Klinik f. Dermatologie

    Lübeck, Germany

  • Praxis Dr. Walker and Dr. Biwer

    Ludwigshafen, Germany

  • Gemeinschaftsprax is für Dermatologie

    Mahlow, Germany

  • Ludwig- Maximilians- Universität München, Klinik für Dermatologie und Allergologie

    München, Germany

  • Germania Campus PraxisKlinik

    Münster, Germany

  • Praxis Dr. Graefe

    Northeim, Germany

  • Haut- und Laserzentrum Potsdam

    Potsdam, Germany

  • Klinik für Dermatologie und Allergologie Klinikum Vest GmbH Recklinghausen

    Recklinghausen, Germany

  • Hautzentrum am Starnberger See GmbH

    Starnberg, Germany

  • Dermatologische Privatpraxis

    Wuppertal, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.